Key Takeaway: The article discusses a pediatric substudy evaluating the safety and efficacy of arimoclomol in patients with Niemann-Pick disease type C, specifically those aged 6 to under 24 months at enrollment. This research will be presented at the International Congress of Inborn Errors of Metabolism in 2025. The focus on young patients highlights the importance of developing treatments for rare diseases.
Price reaction · baseline $8.33 (2025-09-08 close) · hit pre-market · clean, no other ZVRA news in the window
day 0 close · peak
-1.4%
Market Sentiment Analysis
POSITIVE FACTORS
Arimoclomol shows promise for treating Niemann-Pick disease type C.
The study focuses on a vulnerable pediatric population.
Potential for improved safety and efficacy in young patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Medical Publications and Presentations
Safety and efficacy of arimoclomol in a pediatric substudy of Niemann-Pick disease type C patients aged 6 to <24 months at study enrollment
International Congress of Inborn Errors of Metabolism (ICIEM) 2025 - 09/04/2025
Download PDF
Download PDF
Frequently Asked Questions
What is arimoclomol used for?
Arimoclomol is being evaluated for its safety and efficacy in treating Niemann-Pick disease type C.
What age group is involved in the study?
The study focuses on pediatric patients aged 6 to under 24 months.
When will the study results be presented?
Results will be presented at the International Congress of Inborn Errors of Metabolism in 2025.
What disease is being studied?
The study investigates Niemann-Pick disease type C in young patients.